Niagen Bioscience (NASDAQ:NAGE – Get Free Report) and Interparfums (NASDAQ:IPAR – Get Free Report) are both consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Niagen Bioscience and Interparfums, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 4 | 1 | 3.00 |
| Interparfums | 1 | 5 | 2 | 0 | 2.12 |
Niagen Bioscience presently has a consensus target price of $8.50, indicating a potential upside of 310.63%. Interparfums has a consensus target price of $125.29, indicating a potential downside of 7.57%. Given Niagen Bioscience’s stronger consensus rating and higher possible upside, equities analysts plainly believe Niagen Bioscience is more favorable than Interparfums.
Profitability
This table compares Niagen Bioscience and Interparfums’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 12.39% | 17.95% | 13.17% |
| Interparfums | 11.17% | 15.21% | 10.85% |
Risk and Volatility
Niagen Bioscience has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, Interparfums has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
Institutional and Insider Ownership
15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 55.6% of Interparfums shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 43.6% of Interparfums shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Niagen Bioscience and Interparfums”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Niagen Bioscience | $129.42 million | 1.27 | $17.38 million | $0.18 | 11.50 |
| Interparfums | $1.49 billion | 2.92 | $168.39 million | $5.31 | 25.53 |
Interparfums has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.
Summary
Niagen Bioscience beats Interparfums on 8 of the 15 factors compared between the two stocks.
About Niagen Bioscience
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
About Interparfums
Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products in the United States and internationally. It operates in two segments, European Based Operations and United States Based Operations. The company offers its fragrance and cosmetic products under the Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lanvin, Moncler, Montblanc, Rochas, S.T. Dupont, Van Cleef & Arpels, Abercrombie & Fitch, Anna Sui, Donna Karan, DKNY, Emanual Ungaro, Ferragamo, Graff, GUESS, Hollister, MCM, Oscar de la Renta, Ungaro, and Roberto Cavalli brands, as well as French Connection, Intimate, and Dunhill, Lacoste names. It sells its products to department stores, perfumeries, specialty stores, duty free shops, and domestic and international wholesalers, and distributors, as well as through e-commerce. The company was formerly known as Jean Philippe Fragrances, Inc. and changed its name to Inter Parfums, Inc. in July 1999. Inter Parfums, Inc. was founded in 1982 and is headquartered in New York, New York.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
